Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

128.58USD
30 Sep 2016
Change (% chg)

$0.16 (+0.12%)
Prev Close
$128.42
Open
$128.63
Day's High
$129.84
Day's Low
$127.81
Volume
368,169
Avg. Vol
509,679
52-wk High
$131.16
52-wk Low
$67.81

Latest Key Developments (Source: Significant Developments)

Abiomed reports Q1 gaap earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% . Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S . Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Q1 revenue $103 million versus i/b/e/s view $97.2 million .Is increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million.  Full Article

Abiomed reports Q1 GAAP earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 revenue $103 million versus i/b/e/s view $97.2 million . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Abiomed inc says increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million . Abiomed inc says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc gives FY 2017 revenue guidance
Tuesday, 3 May 2016 07:00am EDT 

Abiomed Inc:Gives FY 2017 guidance for total revenues to be in the range of $430 million to $445 million.  Full Article

Abiomed Inc gives Q3 2016 revenue guidance
Monday, 11 Jan 2016 04:00pm EST 

Abiomed Inc:Says reported preliminary unaudited Q3 2016 revenue of approximately $85.8 million.  Full Article

Abiomed announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements
Monday, 17 Aug 2015 08:00am EDT 

Abiomed Inc:Says that it has submitted U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental submissions requesting to expand Impella 2.5 PMA approval to all of the Impella family of devices (Impella 2.5, Impella CP and Impella 5.0/LD).  Full Article

Abiomed Inc announces corporate partnership with Fenway Park
Tuesday, 11 Aug 2015 01:00pm EDT 

Abiomed Inc:Entered into a corporate partnership with Fenway Park and will be bringing its Impella Mobile Learning Lab to the historic baseball stadium tomorrow.  Full Article

Abiomed Inc raises FY 2016 revenue guidance
Tuesday, 4 Aug 2015 07:00am EDT 

Abiomed Inc:Raises FY 2016 guidance for total revenue to be in the range of $300-$310 million.FY 2016 revenue of $292 million - Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc to appoint New Chief Financial Officer Michael Tomsicek
Monday, 1 Jun 2015 04:15pm EDT 

Abiomed Inc:Robert Bowen, Vice President and Chief Financial Officer since 2008 will retire from Abiomed next month and Michael Tomsicek will be appointed as Vice President and Chief Financial Officer, effective July 15.  Full Article

Abiomed raises FY 2016 revenue guidance
Tuesday, 5 May 2015 07:00am EDT 

Abiomed:Says that it is increasing its FY 2016 guidance for total revenue to be in the range of $285 million to $295 million.  Full Article

Abiomed Impella 2.5 receives fda approval for Elective and Urgent High Risk Percutaneous Coronary Intervention (PCI) Procedures
Monday, 23 Mar 2015 05:46pm EDT 

Abiomed:Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Impella 2.5 heart pump during elective and urgent high risk percutaneous coronary intervention (PCI) procedures.Says this approval is based on the extensive clinical data submitted by Abiomed to the FDA to support this PMA as part of the 515 initiative.Impella 2.5, the world's smallest heart pump, is the first hemodynamic support device to receive a PMA indication for use during high risk PCI procedures, demonstrating its safety and effectiveness for this complex patient population.With this approval, the Impella 2.5 is a temporary (* 6 hours) ventricular support device indicated for use during high risk PCI performed in elective or urgent hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction;.When a heart team, including a cardiac surgeon, has determined high risk PCI is the appropriate therapeutic option.Use of the Impella 2.5 in these patients may prevent hemodynamic instability that may occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.  Full Article

BRIEF-Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare

* Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare